What is Rigosertib used for?

Rigosertib is being researched to treat conditions like refractory anemia with excess blasts and various squamous cell carcinomas.

Is Rigosertib an approved drug?

The provided data indicates Rigosertib is in clinical trial phases (up to Phase 3) and does not list a first approval date.

Can Rigosertib treat lung cancer?

Rigosertib is being studied for use in treating squamous cell lung carcinoma.

What kind of molecule is Rigosertib?

Rigosertib is classified as a small molecule.

Is Rigosertib used for head and neck cancer?

Yes, research has looked into using Rigosertib for head and neck squamous cell carcinoma.

What is the status of Rigosertib in clinical trials?

Rigosertib has reached Phase 3 clinical trials for certain indications.

Rigosertib | CAS 592542-59-1 | OWBFCJROIKNMGD

Loading compound...

Small molecule

Rigosertib is a small molecule drug currently being studied in clinical trials. It is being researched for various types of cancer and blood disorders, including certain types of anemia and squamous cell carcinomas.

Used for

Refractory anemia with excess blastsMyelodysplastic syndromeHead and neck squamous cell carcinomaSquamous cell lung carcinomaEsophageal squamous cell carcinomaNeoplasms (tumors)

Conditions

Refractory anemia with excess blastsMyelodysplastic syndromeHead and neck squamous cell carcinomaSquamous cell lung carcinomaEsophageal squamous cell carcinomaNeoplasm

Class

Small molecule

How to take

Rigosertib is currently in clinical development (Phase 3) and is not yet an approved medication for general use in the provided data.

Educational summary derived from FDA labeling, AI-assisted. Not medical advice — consult a healthcare professional. Updated 2026-04-26.

How to take

Frequently asked questions (6)